Convalescent plasma improves survival in COVID-19 patients with blood cancers
SAN ANTONIO (June 17, 2021) -- Convalescent plasma therapy was associated with better survival in blood cancer patients hospitalized with COVID-19, especially in sicker patients. The findings by the COVID-19 and Cancer Consortium (CCC19) are newly published in the peer-reviewed journal JAMA Oncology.
The Mays Cancer Center, home to UT Health San Antonio MD Anderson, is part of the CCC19. The international consortium is composed of 124 medical centers and institutions in North and South America that conduct research to learn how COVID-19 affects cancer patients.
Dimpy Shah, MD, PhD, is an epidemiologist and assistant professor of population health sciences at The University of Texas Health ...










